Hepion to present on CRV431’s anti-fibrotic activity at the Liver Meeting 2019

Hepion Pharmaceuticals

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CSO, Dr. Daren Ure, will present preclinical data on CRV431 at The Liver Meeting 2019.

Dr. Ure’s presentation will address CRV431’s ability to decrease liver fibrosis in a carbon tetrachloride (CCl4) mouse model of liver injury and compare its activity to obeticholic acid, a leading late clinical-phase drug candidate for non-alcoholic steatohepatitis.

In a statement, Dr. Ure said, “Having previously demonstrated CRV431’s ability to reduce liver fibrosis in several studies in experimental NASH, the present findings from a very different experimental model provide strong, additional evidence that direct targeting of fibrotic disease processes in the liver is one of CRV431’s primary mechanisms of action.” 

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.